Arizona · Q5124

Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg in Arizona

Arizona Medicare Avg
$173.44
2% above national avg
National Medicare Avg
$170.85
All states combined
Billed Charge (AZ)
$749.98
What providers submit
Est. Commercial (AZ)
$496.34
National avg: $481.56
Est. Cash / Self-Pay (AZ)
$369.52
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

7.8K
Services in AZ
12
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Arizona

Provider Medicare Services
Alam, Suhail M.D. $176.50 1.9K
Graff, Jordan MD $175.29 1.9K
El-Gasim, Mahmood MD $169.89 1.5K
Itty, Sujit MD $172.05 985
Palejwala, Neal MD $171.37 725
Jamal, Karim M.D. $174.55 181

Arizona Pricing in Context

In Arizona, CPT code Q5124 (Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg) carries an average Medicare payment of $173.44 — 2% above the national benchmark of $170.85. 12 providers across the state submitted claims for this procedure in 2023, performing 7.8K total services. Individual payments in AZ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Arizona is $749.98, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Arizona sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Temporary Codes procedures, the estimated commercial insurance price in Arizona lands near $496.34, with self-pay cash prices typically around $369.52. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg cost in Arizona?

The average Medicare payment for Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg in Arizona is $173.44, which is 2% above the national average of $170.85. Providers in AZ typically bill $749.98 for this procedure.

What does Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg cost with insurance in Arizona?

With commercial insurance in Arizona, Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg costs an estimated $496.34. Without insurance, the estimated cash price is $369.52. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg in Arizona?

12 providers in Arizona billed Medicare for Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg in 2023, performing 7.8K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg cheaper in Arizona than the national average?

No — Injection, Ranibizumab-Nuna, Biosimilar, (byooviz), 0.1 Mg costs 2% above the national average in Arizona. The state average Medicare payment is $173.44 compared to $170.85 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial